1
|
Crew KD, Anderson GL, Arnold KB, Stieb AP, Amenta JN, Collins N, Law CW, Pruthi S, Sandoval-Leon A, Bertoni D, Grosse Perdekamp MT, Colonna S, Krisher S, King T, Yee LD, Ballinger TJ, Braun-Inglis C, Mangino D, Wisinski KB, DeYoung CA, Ross M, Floyd J, Kaster A, Vander Walde L, Saphner T, Zarwan C, Lo S, Graham C, Conlin A, Yost K, Agnese D, Jernigan C, Hershman DL, Neuhouser ML, Arun B, Kukafka R. Making informed choices on incorporating chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial. Contemp Clin Trials 2024:107564. [PMID: 38704119 DOI: 10.1016/j.cct.2024.107564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 04/15/2024] [Accepted: 05/01/2024] [Indexed: 05/06/2024]
Abstract
INTRODUCTION Women with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) have a significantly increased risk of breast cancer, which can be substantially reduced with antiestrogen therapy for chemoprevention. However, antiestrogen therapy for breast cancer risk reduction remains underutilized. Improving knowledge about breast cancer risk and chemoprevention among high-risk patients and their healthcare providers may enhance informed decision-making about this critical breast cancer risk reduction strategy. METHODS/DESIGN We are conducting a cluster randomized controlled trial to evaluate the effectiveness and implementation of patient and provider decision support tools to improve informed choice about chemoprevention among women with AH or LCIS. We have cluster randomized 26 sites across the U.S. through the SWOG Cancer Research Network. A total of 415 patients and 200 healthcare providers are being recruited. They are assigned to standard educational materials alone or combined with the web-based decision support tools. Patient-reported and clinical outcomes are assessed at baseline, after a follow-up visit at 6 months, and yearly for 5 years. The primary outcome is chemoprevention informed choice after the follow-up visit. Secondary endpoints include other patient-reported outcomes, such as chemoprevention knowledge, decision conflict and regret, and self-reported chemoprevention usage. Barriers and facilitators to implementing decision support into clinic workflow are assessed through patient and provider interviews at baseline and mid-implementation. RESULTS/DISCUSSION With this hybrid effectiveness/implementation study, we seek to evaluate if a multi-level intervention effectively promotes informed decision-making about chemoprevention and provide valuable insights on how the intervention is implemented in U.S. CLINICAL SETTINGS TRIAL REGISTRATION NCT04496739.
Collapse
Affiliation(s)
- K D Crew
- Columbia University Irving Medical Center, New York, NY, USA.
| | - G L Anderson
- SWOG Statistics and Data Management Center, Seattle, WA, USA
| | - K B Arnold
- SWOG Statistics and Data Management Center, Seattle, WA, USA
| | - A P Stieb
- Columbia University Irving Medical Center, New York, NY, USA
| | - J N Amenta
- Columbia University Irving Medical Center, New York, NY, USA
| | - N Collins
- Columbia University Irving Medical Center, New York, NY, USA
| | - C W Law
- Columbia University Irving Medical Center, New York, NY, USA
| | - S Pruthi
- Mayo Clinic, Rochester, MN, United States of America
| | - A Sandoval-Leon
- Miami Cancer Institute at Baptist Health South Florida, Miami, FL, USA
| | - D Bertoni
- Good Samaritan Hospital Corvallis, Corvallis, OR , USA
| | | | - S Colonna
- Huntsman Cancer Institute / University of Utah Medical Center, Salt Lake City, UT, USA
| | - S Krisher
- Holy Redeemer Hospital and Medical Center, Meadowbrook, PA, USA
| | - T King
- Dana-Farber Brigham Cancer Center, Brigham and Women's Hospital, Boston, MA, USA
| | - L D Yee
- City of Hope Comprehensive Cancer Center, Duarte, CA, USA
| | - T J Ballinger
- Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA
| | | | - D Mangino
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - K B Wisinski
- University of Wisconsin Carbone Cancer Center, Madison, WI, USA
| | | | - M Ross
- Virginia Commonwealth University, Richmond, VA, USA
| | - J Floyd
- Cancer Care Specialists of Illinois, Heartland NCORP, Decatur, IL, USA
| | - A Kaster
- Sanford Roger Maris Cancer Center, Fargo, ND, United States of America
| | - L Vander Walde
- Baptist Memorial Health Care, Memphis, TN, United States of America
| | | | - C Zarwan
- Lahey Hospital & Medical Center, Burlington, MA, USA
| | - S Lo
- Loyola University Stritch School of Medicine, Maywood, IL, USA
| | - C Graham
- Emory University Hospital/Winship Cancer Institute, Atlanta, GA, USA
| | - A Conlin
- Providence Cancer Institute, Portland, OR, USA
| | - K Yost
- Cancer Research Consortium of West Michigan NCORP, Kalamazoo, MI, USA
| | - D Agnese
- The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
| | - C Jernigan
- Columbia University Irving Medical Center, New York, NY, USA
| | - D L Hershman
- Columbia University Irving Medical Center, New York, NY, USA
| | | | - B Arun
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - R Kukafka
- Columbia University Irving Medical Center, New York, NY, USA
| |
Collapse
|
2
|
Helzer KT, Sharifi MN, Sperger JM, Shi Y, Annala M, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause HK, Schehr JL, Sethakorn N, Kosoff D, Kyriakopoulos C, Burkard ME, Rydzewski NR, Yu M, Harari PM, Bassetti M, Blitzer G, Floberg J, Sjöström M, Quigley DA, Dehm SM, Armstrong AJ, Beltran H, McKay RR, Feng FY, O'Regan R, Wisinski KB, Emamekhoo H, Wyatt AW, Lang JM, Zhao SG. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Ann Oncol 2023; 34:813-825. [PMID: 37330052 PMCID: PMC10527168 DOI: 10.1016/j.annonc.2023.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 05/30/2023] [Accepted: 06/06/2023] [Indexed: 06/19/2023] Open
Abstract
BACKGROUND The isolation of cell-free DNA (cfDNA) from the bloodstream can be used to detect and analyze somatic alterations in circulating tumor DNA (ctDNA), and multiple cfDNA-targeted sequencing panels are now commercially available for Food and Drug Administration (FDA)-approved biomarker indications to guide treatment. More recently, cfDNA fragmentation patterns have emerged as a tool to infer epigenomic and transcriptomic information. However, most of these analyses used whole-genome sequencing, which is insufficient to identify FDA-approved biomarker indications in a cost-effective manner. PATIENTS AND METHODS We used machine learning models of fragmentation patterns at the first coding exon in standard targeted cancer gene cfDNA sequencing panels to distinguish between cancer and non-cancer patients, as well as the specific tumor type and subtype. We assessed this approach in two independent cohorts: a published cohort from GRAIL (breast, lung, and prostate cancers, non-cancer, n = 198) and an institutional cohort from the University of Wisconsin (UW; breast, lung, prostate, bladder cancers, n = 320). Each cohort was split 70%/30% into training and validation sets. RESULTS In the UW cohort, training cross-validated accuracy was 82.1%, and accuracy in the independent validation cohort was 86.6% despite a median ctDNA fraction of only 0.06. In the GRAIL cohort, to assess how this approach performs in very low ctDNA fractions, training and independent validation were split based on ctDNA fraction. Training cross-validated accuracy was 80.6%, and accuracy in the independent validation cohort was 76.3%. In the validation cohort where the ctDNA fractions were all <0.05 and as low as 0.0003, the cancer versus non-cancer area under the curve was 0.99. CONCLUSIONS To our knowledge, this is the first study to demonstrate that sequencing from targeted cfDNA panels can be utilized to analyze fragmentation patterns to classify cancer types, dramatically expanding the potential capabilities of existing clinically used panels at minimal additional cost.
Collapse
Affiliation(s)
- K T Helzer
- Department of Human Oncology, University of Wisconsin, Madison
| | - M N Sharifi
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - J M Sperger
- Department of Medicine, University of Wisconsin, Madison, USA
| | - Y Shi
- Department of Human Oncology, University of Wisconsin, Madison
| | - M Annala
- Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - M L Bootsma
- Department of Human Oncology, University of Wisconsin, Madison
| | - S R Reese
- Department of Human Oncology, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - A Taylor
- Department of Medicine, University of Wisconsin, Madison, USA
| | - K R Kaufmann
- Department of Medicine, University of Wisconsin, Madison, USA
| | - H K Krause
- Department of Medicine, University of Wisconsin, Madison, USA
| | - J L Schehr
- Carbone Cancer Center, University of Wisconsin, Madison
| | - N Sethakorn
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - D Kosoff
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - C Kyriakopoulos
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - M E Burkard
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - N R Rydzewski
- Department of Human Oncology, University of Wisconsin, Madison
| | - M Yu
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison
| | - P M Harari
- Department of Human Oncology, University of Wisconsin, Madison; Carbone Cancer Center, University of Wisconsin, Madison
| | - M Bassetti
- Department of Human Oncology, University of Wisconsin, Madison; Carbone Cancer Center, University of Wisconsin, Madison
| | - G Blitzer
- Department of Human Oncology, University of Wisconsin, Madison; Carbone Cancer Center, University of Wisconsin, Madison
| | - J Floberg
- Department of Human Oncology, University of Wisconsin, Madison; Carbone Cancer Center, University of Wisconsin, Madison
| | - M Sjöström
- Department of Radiation Oncology, University of California San Francisco, San Francisco; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco
| | - D A Quigley
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco; Departments of Epidemiology and Biostatistics; Urology, University of California San Francisco, San Francisco
| | - S M Dehm
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis
| | - A J Armstrong
- Duke Cancer Institute Center for Prostate and Urologic Cancers, Department of Medicine, Duke University, Durham
| | - H Beltran
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston
| | - R R McKay
- Moores Cancer Center, University of California San Diego, La Jolla
| | - F Y Feng
- Department of Radiation Oncology, University of California San Francisco, San Francisco; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco
| | - R O'Regan
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA; Department of Medicine, University of Rochester, Rochester, USA
| | - K B Wisinski
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - H Emamekhoo
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - A W Wyatt
- Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - J M Lang
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - S G Zhao
- Department of Human Oncology, University of Wisconsin, Madison; Carbone Cancer Center, University of Wisconsin, Madison; William S. Middleton Memorial Veterans' Hospital, Madison, USA.
| |
Collapse
|
3
|
Griffiths JI, Chen J, Cosgrove PA, O'Dea A, Sharma P, Ma CX, Trivedi M, Kalinsky K, Wisinski KB, O'Reagan R, Makhoul I, Spring LM, Bardia A, Adler FR, Cohen AL, Chang JT, Khan QJ, Bild AH. Abstract SP012: Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine signaling inhibitors. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-sp12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Combining cyclin-dependent kinase (CDK) inhibitors with endocrine therapy improves outcomes for metastatic estrogen receptor positive (ER+), HER2 negative, breast cancer patients. However, the value of this combination in potentially curable earlier stage patients is not clear. Using single cell transcriptomic profiling, we examined the evolutionary trajectories of early stage breast cancer tumors using serial tumor biopsies from a clinical trial of preoperative endocrine therapy alone (letrozole) or in combination with the cell cycle inhibitor ribociclib. Applying hierarchical regression and Gaussian process mathematical modelling, we classified each tumor by whether it shrinks or persists with therapy and determined cancer phenotypes related to evolution of resistance and cell cycle transcriptional rewiring. We found that all patients’ tumors undergo subclonal evolution during therapy, irrespective of the clinical response. However, tumors subjected to endocrine therapy alone showed reduced diversity over time, those facing combination therapy exhibited increased diversity. Despite different diversity, single nuclei RNA sequencing uncovered common phenotypic changes in tumor cells that persist following treatment. In these tumors, accelerated loss of estrogen signaling is convergent with up-regulation of the JNK pathway, while persistent tumors that maintain estrogen signaling during therapy show potentiation of CDK4/6 activation consistent with ERBB4 and ERK signaling up-regulation. Cell cycle reconstruction identified that these tumors can rebound during combination therapy treatment, indicating stronger selection and promotion of a proliferative state. These results indicate that combination therapy in early stage ER+ breast cancers with ER and CDK inhibition drives rapid evolution of resistance via a shift from estrogen signaling to alternative growth factor receptor mediated proliferation and JNK signaling activation, concordant with a bypass in the G1 checkpoint.
Citation Format: JI Griffiths, J Chen, PA Cosgrove, A O'Dea, P Sharma, CX Ma, M Trivedi, K Kalinsky, KB Wisinski, R O'Reagan, I Makhoul, LM Spring, A Bardia, FR Adler, AL Cohen, JT Chang, QJ Khan, AH Bild. Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine signaling inhibitors [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr SP012.
Collapse
Affiliation(s)
| | - J Chen
- 1City of Hope, Duarte, CA
| | | | - A O'Dea
- 2University of Kanas Medical Center, Westwood, KS
| | | | - CX Ma
- 4Washington University School of Medicine, St. Louis, MO
| | - M Trivedi
- 5Columbia University Irving Medical Center, New York, NY
| | - K Kalinsky
- 5Columbia University Irving Medical Center, New York, NY
| | - KB Wisinski
- 6University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - R O'Reagan
- 6University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - I Makhoul
- 7University of Arkansas for Medical Sciences, Little Rock, AR
| | - LM Spring
- 8Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
| | | | - FR Adler
- 9University of Utah, Salt Lake City, UT
| | - AL Cohen
- 10Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
| | - JT Chang
- 11UT Health Sciences Center at Houston, Houston, TX
| | - QJ Khan
- 12University of Kansas Medical Center, DuarteWestwood, KS
| | | |
Collapse
|
4
|
Santa-Maria CA, Rampurwala M, Wisinski K, Toppmeyer D, O'Regan R. Abstract OT1-05-01: A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot1-05-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple negative breast cancer (TNBC) is a heterogeneous disease encompassing distinct intrinsic molecular subtypes, including a luminal androgen receptor (AR) subtype, characteristically dependent on AR signaling. The AR is expressed in more than 50% of TNBCs. Bicalutamide is an oral, non-steroidal, AR antagonist, which has been studied in metastatic TNBC with a clinical benefit rate of 19% at 24 weeks. In preclinical models, cyclin dependant kinase (CDK) 4/6 inhibition has been shown to restore sensitivity to AR inhibition, and may thus be an important resistance mechanism. Ribociclib is an orally bioavailable, highly specific CDK4/6 inhibitor that induces cell cycle arrest, already approved in endocrine receptor positive breast cancers. We hypothesize that inhibition of CDK inhibition can enhance the activity of anti-androgen therapy in TNBC that express AR.
Methods: We designed a phase I/II, single arm, non-randomized, open label study of the combination of bicalutamide with ribociclib in women with advanced AR-positive TNBC. The primary objective of the phase I component is to determine the maximum tolerated dose of the combination, and of the phase II component to assess the clinical benefit rate at 16 weeks. Secondary objectives include progression free and overall survival, objective response rates, and safety and tolerability. Exploratory objectives will be to assess AR quantification, localization and splice variants in circulating tumor cells, as well as quantification of pan and phospho proteins of Rb. Eligible patients must have measurable metastatic or unresectable AR-positive TNBC and have had no more than 1 line of systemic therapy for metastatic disease. The phase I study will be conducted using a 3+3 dose escalation schema, 12 to 18 patients are expected to enroll. The phase II component will utilize a Simon's two stage design, enrolling 24 patients for the first stage. At least 5 subjects must have clinical benefit by 16 weeks to proceed onto the second stage, which would enroll an additional 22 subjects for a total of 46 patients. The study will be powered to detect a clinical benefit rate of 40% with a power of 80% and a type I error rate of 10%. Contact dmusapatika@hoosiercancer.org for more information about the study.
Citation Format: Santa-Maria CA, Rampurwala M, Wisinski K, Toppmeyer D, O'Regan R. A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor, in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT1-05-01.
Collapse
Affiliation(s)
- CA Santa-Maria
- Northwestern University; University of Chicago; University of Wisconsin; Rutgers University
| | - M Rampurwala
- Northwestern University; University of Chicago; University of Wisconsin; Rutgers University
| | - K Wisinski
- Northwestern University; University of Chicago; University of Wisconsin; Rutgers University
| | - D Toppmeyer
- Northwestern University; University of Chicago; University of Wisconsin; Rutgers University
| | - R O'Regan
- Northwestern University; University of Chicago; University of Wisconsin; Rutgers University
| |
Collapse
|
5
|
Danciu OC, Hoskins K, Tamkus D, Truica C, Blaes A, Green L, Liu L, Toppmeyer D, Wisinski K. Abstract OT3-05-10: A single arm phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Hormone receptor positive breast cancer is the most commonly diagnosed subset of breast cancer (60-65%). Endocrine therapy is effective for this subset of breast cancer, in both the adjuvant and metastatic settings. Despite advances in endocrine therapy, many patients relapse during or after completing adjuvant therapy and metastatic breast cancer remains incurable. Palbociclib is a reversible, oral, small molecule inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6). CDK4 and CDK6 together with cyclin D have important roles in regulation of the G1/S transition via regulation of the phosphorylation state of retinoblastomaprotein (Rb). Palbociclib showed significantly improved progression-free survival taken together with endocrine agents in treatment of metastatic breast cancer. Preclinical data showed that in combination with tamoxifen, palbociclib had synergistic growth inhibitory activity as well as efficacy in a model of acquired tamoxifen resistance. Combining palbociclib with tamoxifen in first line treatment of metastatic hormone receptor positive breast cancer may offers an appealing alternative to other endocrine combinations. Methods: This is a non-randomized, open-label, single-arm, multicenter, phase II study of palbociclib in combination with tamoxifen in patients with hormone receptor positive/HER2 negative advanced breast cancer. The primary objective is to determine the objective response rate (complete or partial response) based on RECIST 1.1 or MDA Criteria (for patients with bone only disease). Secondary objectives are: safety and tolerability, progression-free survival, clinical benefit rate, 2-year overall survival. Correlative objectives will explore alterations in circulating tumor DNA and changes in gene expression pattern at the time of progression. Eligibility criteria: women or men with diagnosis of hormone receptor positive/ HER2 negative locally advanced or metastatic breast cancer, not amenable to curative surgery; no prior systemic anti-cancer therapy for advanced hormone receptor positive breast cancer; adequate organ function; pre and post menopausal women are allowed. Drug administration: palbociclib dose will be 125 mg orally once daily on days 1-21 of each 28-day cycle; tamoxifen dose will be 20 mg orally once daily for every day of the 28-day cycle. As of June 2017, the study enrolled 10/71 patients and it is still open to enrollment. NCT 02668666; ocdanciu@uic.edu
Citation Format: Danciu OC, Hoskins K, Tamkus D, Truica C, Blaes A, Green L, Liu L, Toppmeyer D, Wisinski K. A single arm phase II study of palbociclib in combination with tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-05-10.
Collapse
Affiliation(s)
- OC Danciu
- University of Illinois at Chicago, Chicago, IL; Michigan State University, Lansing, MI; Penn State Cancer Institute, Hershey, PA; University of Minnesota, Minneapolis, MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Wisconsin, Madison, WI
| | - K Hoskins
- University of Illinois at Chicago, Chicago, IL; Michigan State University, Lansing, MI; Penn State Cancer Institute, Hershey, PA; University of Minnesota, Minneapolis, MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Wisconsin, Madison, WI
| | - D Tamkus
- University of Illinois at Chicago, Chicago, IL; Michigan State University, Lansing, MI; Penn State Cancer Institute, Hershey, PA; University of Minnesota, Minneapolis, MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Wisconsin, Madison, WI
| | - C Truica
- University of Illinois at Chicago, Chicago, IL; Michigan State University, Lansing, MI; Penn State Cancer Institute, Hershey, PA; University of Minnesota, Minneapolis, MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Wisconsin, Madison, WI
| | - A Blaes
- University of Illinois at Chicago, Chicago, IL; Michigan State University, Lansing, MI; Penn State Cancer Institute, Hershey, PA; University of Minnesota, Minneapolis, MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Wisconsin, Madison, WI
| | - L Green
- University of Illinois at Chicago, Chicago, IL; Michigan State University, Lansing, MI; Penn State Cancer Institute, Hershey, PA; University of Minnesota, Minneapolis, MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Wisconsin, Madison, WI
| | - L Liu
- University of Illinois at Chicago, Chicago, IL; Michigan State University, Lansing, MI; Penn State Cancer Institute, Hershey, PA; University of Minnesota, Minneapolis, MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Wisconsin, Madison, WI
| | - D Toppmeyer
- University of Illinois at Chicago, Chicago, IL; Michigan State University, Lansing, MI; Penn State Cancer Institute, Hershey, PA; University of Minnesota, Minneapolis, MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Wisconsin, Madison, WI
| | - K Wisinski
- University of Illinois at Chicago, Chicago, IL; Michigan State University, Lansing, MI; Penn State Cancer Institute, Hershey, PA; University of Minnesota, Minneapolis, MN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; University of Wisconsin, Madison, WI
| |
Collapse
|
6
|
Tevaarwerk AJ, Buhr KA, Conkright W, Onitilo A, Robinson E, Hegeman R, Ahuja H, Kwong RW, Nanad R, Dennee A, Koehn T, Burkard ME, Wisinski KB, Wiegmann DA, Sesto ME. Abstract P5-13-03: Prospective study of work limitations in breast cancer patients (pts) undergoing curative chemotherapy (CTx). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-13-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- AJ Tevaarwerk
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - KA Buhr
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - W Conkright
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - A Onitilo
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - E Robinson
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - R Hegeman
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - H Ahuja
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - RW Kwong
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - R Nanad
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - A Dennee
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - T Koehn
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - ME Burkard
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - KB Wisinski
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - DA Wiegmann
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| | - ME Sesto
- University of Wisconsin, Madison, WI; Marshfield Clinics, Weston Center, WI; Fox Valley Hematology and Oncology, WI; Mercy Health System Hematology/Oncology Clinic, WI; Aspirus Regional Cancer Center, WI; Gunderson Lutheran Health System, WI; Columbia St. Mary's, Milwaukee, WI
| |
Collapse
|
7
|
Turk A, Chan N, Leal T, O'Regan R, Tevaarwerk A, Rice L, Campbell T, Barroilhet L, Mehnert J, Eickhoff J, Kolesar J, Liu G, Wisinski K. Abstract P4-22-21: NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Poly(ADP-ribose) polymerase (PARP) enzymes are involved in DNA repair and activated by DNA strand breaks. DNA damage from carboplatin is associated with activation of PARP. Preclinical data indicate that PARP inhibition potentiates the anti-tumor effect of platinum chemotherapy. Talazoparib (T) is an oral, selective PARP inhibitor with a single agent maximum tolerated dose (MTD) of 1mg orally qd. Primary dose-limiting toxicity (DLT) was thrombocytopenia. This phase I study combines T with the commonly used chemotherapy regimen of carboplatin (C) and paclitaxel (P).
Methods: Two dosing schedules are being investigated. In both schedules, C is administered on day 1 and P on days 1, 8, and 15 of a 21-day cycle. T (100-1000mcg) is dosed once daily for days 1-7 (schedule A) or days 1-3 (schedule B) starting on day 1. A 3+3 design is used for dose escalation. Key eligibility criteria include age 318 with a measurable or evaluable solid incurable malignancy. Patients (pts) must have tumor type that is expected to respond to C + P or have BRCA germline or somatic mutation. Stable, treated brain metastases are allowed. No prior C for metastatic disease is allowed. Pts must have platelets>150 and no need for anticoagulation. After 4-6 cycles of combination therapy, pts may continue the combination, change to C and intermittent T without P or change to T alone with continuous daily dosing. Each schedule will have a 6 subject dose expansion at the MTD. The starting dose level for schedule B will be the MTD from schedule A.
Results: Schedule A cohort results are reported: 11 pts (median age 59 [range 39-68]; 8 female; 3 male) have been enrolled. Pts had breast (6), ovarian (2), pancreatic (1), and SCC of oropharynx (1) and concurrent ovarian and pancreatic (1). Five pts are BRCA2+ and 3 pts are BRCA1+. Dose level 3 on schedule A (T 350mcg with C AUC 6 and P 80mg/m2) exceeded the MTD with 2 of 3 pts experiencing hematologic dose limiting toxicities (DLTs) including 1 pt with grade (gr) 3 neutropenic fever and gr 4 thrombocytopenia and another pt with grade 3/4 neutropenia lasting > 7 days. Most common AEs include neutropenia (grade 3-4: 7), anemia (grade 3-4: 3), and thrombocytopenia (grade 3-4: 4). Results from expansion of dose level 2 (T 250mcg with C AUC 6 and T 80mg/m2) will be presented. The 11 pts were on study a median of 9 weeks (range 9-36+). Four pts have discontinued study therapy: 1 due to need for anticoagulation for PE, 1 for prolonged cytopenias, and 2 for disease progression. Of the 8 pts with measurable disease evaluated for response to date, 4 had SD, 1 had a cPR, 1 had radiographic CR, and 2 with PD. A pt with BRCA 1+ triple negative breast cancer has maintained a prolonged PR (36+ weeks) even after dose reductions to T 100mcg with C AUC 3. One pt with ovarian cancer (BRCA WT) has radiographic CR (CA 125 remains mildly elevated) after 15+ weeks of therapy.
Conclusion: PARP inhibition with talazoparib days 1-7 in combination with carboplatin and paclitaxel leads to DLT of myelosuppression. However, clinical responses are seen even with lower dose combinations.
Citation Format: Turk A, Chan N, Leal T, O'Regan R, Tevaarwerk A, Rice L, Campbell T, Barroilhet L, Mehnert J, Eickhoff J, Kolesar J, Liu G, Wisinski K. NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-21.
Collapse
Affiliation(s)
- A Turk
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - N Chan
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - T Leal
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - R O'Regan
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - A Tevaarwerk
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - L Rice
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - T Campbell
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - L Barroilhet
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - J Mehnert
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - J Eickhoff
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - J Kolesar
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - G Liu
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - K Wisinski
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| |
Collapse
|
8
|
Childs JS, Higgins DM, DeShong K, Heckman-Stoddard BM, Wojtowicz ME, Stanton SE, Bailey HH, Wisinski KB, Disis ML. Abstract OT3-01-03: A phase I trial of the safety and immunogenicity of a DNA plasmid based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-01-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Three proteins insulin like growth factor binding protein 2 (IGFBP2), human epidermal growth factor receptor 2 (HER2), and insulin like growth factor receptor-1 (IGF1R) are overexpressed in in pre-invasive and high risk breast lesions and are associated with progression to invasive breast cancer. These proteins are immunogenic and elicit both humoral and cellular immunity in breast cancer patients. It is hypothesized that immunization with a plasmid vaccine (WOKVAC) targeting antigens from these proteins will be safe and immunogenic. WOKVAC has been designed to include extended sequences of the immunizing antigens that are predominantly associated with eliciting Type I immune responses. Type I immunity results in immune cells called T-cells secreting high levels of inflammatory cytokines (called Th1) that stimulate tumor destruction as well as the generation of cytotoxic T-cells that can directly kill the tumors.
Trial design: Phase I dose escalation study of 3 doses of WOKVAC admixed with 100mcg of GM-CSF. Patients will be assigned sequentially to one of three arms (10 patients/arm): Arm 1=150mcg, Arm 2=300mcg, Arm 3=600mcg. Each dose arm will have a staggered enrollment to assess toxicity. If the Arm 1 dose is determined to be safe, Arm 2 patients can be enrolled. If the Arm 2 dose is safe and immunologically more efficacious than Arm 1 then Arm 3 patients can be enrolled. Study treatment includes 3 monthly vaccines, two evaluations at 1 and 6 months post vaccine and a 5 year follow-up to collect reports from the patient's primary oncologist. Toxicity is assessed at baseline through the end of the study. Serial blood draws for immunologic monitoring is done.
Eligibility criteria: Patients with non-metastatic, node positive, HER2 negative breast cancer that is in remission and defined as no evidence of disease. Patients must have a good performance status, be at least 28 days from last cytotoxic chemotherapy and/or radiotherapy and 28 days from any use of systemic steroids.
Specific aims: (1) Determine safety of 3 escalating doses of WOKVAC, (2) Determine the most immunogenic dose, (3) Determine whether a WOKVAC Th1 polyepitope plasmid based vaccine elicits a persistent memory T-cell and (4) Determine whether WOKVAC vaccination modulates T regulatory cells and myeloid derived suppressor cells.
Statistical methods: (1) Safety will be assessed per NCI CTCAE v. 4.0, (2) Immunogenicity will be defined by the magnitude of the Th1 IFN-gamma antigen specific immune response. Successful immunization is a protein specific IFN-g precursor frequency greater than 1:20,000 PBMC for each antigen or 2 fold increase if baseline immune response (3) The IGFBP2, HER2, and IGF1R specific IFN-g/IL-10 ratios by ELISPOT will be evaluated to determine that a predominantly Th1 immune response is stimulated, and (4) Humoral immune response will be measured by ELISA and serum antibody avidity for IGFBP2, HER2, and IGF1R to determine an avidity index (AI) before and after vaccination.
Targeted Accrual: 30 patients
Contact information:
University of Washington: 866-392-8588/TrialTVG@uw.edu
University of Wisconsin: 608-265-2493/prevention@uwcarbone.wisc.edu.
Citation Format: Childs JS, Higgins DM, DeShong K, Heckman-Stoddard BM, Wojtowicz ME, Stanton SE, Bailey HH, Wisinski KB, Disis ML. A phase I trial of the safety and immunogenicity of a DNA plasmid based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-01-03.
Collapse
Affiliation(s)
- JS Childs
- University of Washington, Seattle, WA; University of Wisconsin, Madison, WI; NCI, NIH, Bethesda, MD
| | - DM Higgins
- University of Washington, Seattle, WA; University of Wisconsin, Madison, WI; NCI, NIH, Bethesda, MD
| | - K DeShong
- University of Washington, Seattle, WA; University of Wisconsin, Madison, WI; NCI, NIH, Bethesda, MD
| | - BM Heckman-Stoddard
- University of Washington, Seattle, WA; University of Wisconsin, Madison, WI; NCI, NIH, Bethesda, MD
| | - ME Wojtowicz
- University of Washington, Seattle, WA; University of Wisconsin, Madison, WI; NCI, NIH, Bethesda, MD
| | - SE Stanton
- University of Washington, Seattle, WA; University of Wisconsin, Madison, WI; NCI, NIH, Bethesda, MD
| | - HH Bailey
- University of Washington, Seattle, WA; University of Wisconsin, Madison, WI; NCI, NIH, Bethesda, MD
| | - KB Wisinski
- University of Washington, Seattle, WA; University of Wisconsin, Madison, WI; NCI, NIH, Bethesda, MD
| | - ML Disis
- University of Washington, Seattle, WA; University of Wisconsin, Madison, WI; NCI, NIH, Bethesda, MD
| |
Collapse
|
9
|
Khan QJ, Prochaska LH, Mohammad J, Yuan Y, O'Dea A, Bardia A, Wisinski K, Hard M, Baccaray S, Makhoul I, Wagner J, Laura S, Ma C, Sharma P. Abstract OT3-02-06: Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-02-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
In early ER+ breast cancer, neo-adjuvant (NA) endocrine therapy (ET) may identify a subset of patients with endocrine sensitive disease with excellent outcomes without chemotherapy. In patients receiving a NA aromatase inhibitor, on- therapy, short term (day 14) Ki-67 of <10% and post NA pre-operative endocrine prognostic index (PEPI) 0 at surgery are associated with low relapse rates without chemotherapy. Ribociclib, a novel CDK4/6 inhibitor is active in ER+ metastatic breast cancer. We hypothesize that ribociclib+letrozole as NA ET for stage II-III breast cancer will increase the number of women with a PEPI 0 at surgery.
Trial Design:
Randomized, placebo-controlled, multi-center, phase II, investigator initiated trial of NA letrozole +/- ribociclib in postmenopausal women with ER+, HER2-, breast cancer. Subjects will be randomized 1:1:1 to letrozole 2.5 mg daily + placebo, letrozole 2.5mg daily + ribociclib 600mg daily on D1-21 of a 28 day cycle (intermittent dosing), or letrozole 2.5mg daily + ribociclib 400mg daily (continuous dosing). Treatment will be continued for 6 months followed by surgery. Research core biopsies and blood will be collected at baseline, at day 14, and at surgery. A Ki67 >10% at day 14 will result in discontinuation of the subject from the protocol as this may be an early indicator of resistance to endocrine therapy. An MRI will be done after 2 months of therapy to assess response/progression. Primary endpoint is a PEPI score of 0 at surgery.
Key Eligibility Criteria:
Postmenopausal (natural or surgical) women with stage II/III ER+, HER2- breast cancer. Must have a palpable breast mass of at least 2 cm. Multicentric/contralateral invasive disease not allowed. Ipsilateral/contralateral DCIS is allowed. Inflammatory breast cancer is excluded.
Specific Aims:
Primary objective: To determine if ribociclib+letrozole as a 24 week NA ET increases rate of PEPI score of 0 at surgery compared to letrozole. Secondary objectives: To determine if ribociclib+letrozole as a 24 week NA ET increases the proportion of tumors with complete cell cycle arrest compared to letrozole; to determine if ribociclib in combination with letrozole for 24 weeks results in improved 5 year RFS compared to letrozole; to examine differences in response rates between the two ribociclib containing arms vs letrozole.
Statistical Methods:
The two ribocilib containing arms (n=80) will be combined for analysis against placebo + letrozole (n=40). Assuming that addition of ribociclib will increase the rate of PEPI 0 by 20%, and setting Type I error rate at 10% and Type II error rates at 20% in the final analysis, a sample size of 80 women in the treatment arms (40 in each arm) and 40 women in the control arm are needed to show significance.
Patient accrual and target accrual:
Participating sites include The Univ of Kansas Med Ctr, City of Hope National Med Ctr, Massachusetts General Hospital, University of Miami Sylvester Comprehensive Cancer Ctr, University of Arkansas for Medical Sciences, and University of Wisconsin. The trial has accrued 16 patients with a target accrual of 120 patients. Accrual should be complete in 2/2017.
Contact information: Qamar Khan, MD (qkhan@kumc.edu).
Citation Format: Khan QJ, Prochaska LH, Mohammad J, Yuan Y, O'Dea A, Bardia A, Wisinski K, Hard M, Baccaray S, Makhoul I, Wagner J, Laura S, Ma C, Sharma P. Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-02-06.
Collapse
Affiliation(s)
- QJ Khan
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - LH Prochaska
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - J Mohammad
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - Y Yuan
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - A O'Dea
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - A Bardia
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - K Wisinski
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - M Hard
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - S Baccaray
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - I Makhoul
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - J Wagner
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - S Laura
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - C Ma
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| | - P Sharma
- University of Kansas Medical Center, Kansas City, KS; University of Miami Health System, Miami, FL; City of Hope, Duarte, CA; Massachusetts General Hospital, Boston, MA; University of Wisconsin, Madison, WI; University of Arkansas for Medical Sciences, Little Rock, AR; Washington University Medical School, St. Louis, MO
| |
Collapse
|
10
|
Lillian S, De Bono J, Higano C, Shapiro G, Brugger W, Mitchell P, Colebrook S, Klinowska T, Barry S, Dean E, Martin-Mills J, Wisinski K, Moorthy G, Mills J, Cruzalegui F, Tolaney S, Lang J, Jose De Miquel Luken M, Kunar R, Chatta G. AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32637-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Mullvain JA, Leal T, Eickhoff J, Kolesar JM, Liu G, DiPaola RS, Wisinski KB. Abstract OT3-02-06: A phase 1 study of BMN 673 in combination with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot3-02-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Poly(ADP-ribose) polymerase (PARP) enzymes are involved in DNA repair and are activated by DNA strand breaks. DNA damage from carboplatin has been associated with activation of PARP. Preclinical data indicate that PARP inhibition potentiates the anti-tumor effect of platinum chemotherapy. BMN 673 (Talazoparib) is an oral, selective PARP inhibitor. The phase I single agent maximum tolerated dose (MTD) of BMN 673 given once daily was 1mg po qd. Myelosuppresion was primary dose-limiting toxicity (DLT), including grade 3-4 thrombocytopenia. Carboplatin with paclitaxel is a current standard treatment for many solid tumors, including ovarian, bladder, upper gastrointestinal, breast and non-small cell lung cancer. Myelosuppression, including thrombocytopenia, is also seen with this combination. This phase 1 study is combining BMN 673 with carboplatin once every 3 weeks and weekly paclitaxel.
Trial Design: Two dosing schedules are being investigated. In both schedules intravenous carboplatin will be administered on day 1 and paclitaxel on days 1, 8, 15 of a 21-day cycle. BMN 673 will be dosed orally once daily for days 1-7 (schedule A) or days 1-3 (schedule B) starting on day 1 of each cycle. After 4-6 cycles of the combination therapy, subjects may continue the combination, change to carboplatin and intermittent BMN 673 without paclitaxel or change to BMN 673 alone with continuous daily dosing. Each schedule will have a 6 subject dose expansion at the MTD. The starting dose level for schedule B will be the MTD from Schedule A. The MTD for each schedule will be considered the recommended phase 2 dose (RP2D). Pharmacokinetic samples will be collected. Planned exploratory correlative studies include RAD51 and gamma-H2AX changes in peripheral blood mononuclear cells and examination of mechanism of secondary resistance by comparing mutation profiles in tumors from biopsy specimens.
Key eligibility criteria include age 18 or older with a measurable or evaluable solid tumor malignancy that is metastatic or unresectable. Subjects must have tumor type for which there is a reasonable expectation of response to carboplatin and paclitaxel or they must have BRCA germline or somatic mutation. Adequate performance status and organ function is required. Stable, treated brain metastases are allowed. No prior carboplatin for metastatic disease is allowed.
Objectives: The primary objectives are to determine the MTD and RP2D of BMN 673 given on the 7 and 3 day schedules in combination with carboplatin and paclitaxel. Secondary objectives include evaluation of the anti-tumor activity, pharmacokinetic parameters, and the safety and tolerability of the combination.
Statistical Plan: A standard 3+3 phase 1 dose escalation design is used. Assuming 3-6 subjects per dose level with two schedules including 6 subject dose expansion cohorts and assuming 6 inevaluable subjects, the maximum sample size is 66.
Study Status: The trial will be activating in summer 2015 at the Cancer Institute of New Jersey and University of Wisconsin. It is anticipated that 2-3 patients will be accrued per month with accrual completed within 28 months. For more information: www.clinicaltrials.gov (NCT02317874).
Citation Format: Mullvain JA, Leal T, Eickhoff J, Kolesar JM, Liu G, DiPaola RS, Wisinski KB. A phase 1 study of BMN 673 in combination with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT3-02-06.
Collapse
Affiliation(s)
- JA Mullvain
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - T Leal
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - J Eickhoff
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - JM Kolesar
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - G Liu
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - RS DiPaola
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| | - KB Wisinski
- University of Wisconsin Carbone Cancer Center, Madison, WI; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
| |
Collapse
|
12
|
Wisinski KB, Burkard ME, Njiaju U, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor A, Tevaarwerk A. Abstract P3-12-10: Feasibility of four cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A Wisconsin oncology network study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-12-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Dose-dense therapies have had a major impact on reducing toxicity and improving outcomes in breast cancer. A combination of docetaxel plus cyclophosphamide (TC) every 3 weeks has emerged as a common chemotherapy regimen used for treatment of node-negative or lower-risk node-positive breast cancer. We tested whether it is feasible to deliver TC on a dose-dense schedule.
Patients and Methods: We enrolled women with early stage breast cancer on a single-arm phase II study of adjuvant dose-dense TC (ddTC) through a regional oncology network (WON). All women completed primary surgery; subsequent therapy with TC was deemed appropriate by the treating physician. Planned treatment was docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles with subcutaneous pegfilgrastim 6 mg administered 24-48 hours after the administration of each chemotherapy cycle. The primary endpoint was feasibility of administering therapy within 10 weeks. A Simon Optimal 2-Stage design was employed for the study design.
Results: Of 42 women enrolled, 41 were evaluable by prespecified criteria. Median age was 54 (28-73). Most subjects had node negative (73%) or hormone receptor positive (71%) tumors. Of the 41 subjects, 37 (90.2%) completed therapy within 10 weeks and 34 (83%) completed therapy at 8 weeks without dose modification. Rates of grade 2 neuropathy were similar to that reported previously (15%) and there were no cases of grade 3 or higher neuropathy. The rate of neutropenic fever was low (2.5%). Rash and plantar/palmar erythrodythesia were common and reached grade 3 in four subjects (9.8%).
Conclusion: Dose-dense TC is feasible with tolerability profiles similar to standard TC and a low likelihood of neutropenic fever. This study supports further clinical development of this 8-week adjuvant chemotherapy regimen.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-12-10.
Collapse
Affiliation(s)
- KB Wisinski
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - ME Burkard
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - U Njiaju
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - S Donohue
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - R Hegeman
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - A Stella
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - P Mansky
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - V Shah
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - T Goggins
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - R Qamar
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - L Dietrich
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - K Kim
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - A Traynor
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| | - A Tevaarwerk
- University of Wisconsin Carbone Cancer Center, Madison, WI; Bellin Memorial Hospital, Green Bay, WI; Columbia St. Mary's, Milwaukee, WI; Fox Valley Hematology and Oncology, Appleton, WI; Aurora Cancer Care, Wauwatosa, WI; Gunderson Lutheran Health System, Lacrosse, WI
| |
Collapse
|
13
|
Custer JL, Rocque GB, Wisinski KB, Jones NR, Donohue S, Koehn TM, Champeny TL, Terhaar AR, Chen KB, Peck KA, Tun MT, Wiegmann DA, Sesto ME, Tevaarwerk AJ. Abstract P2-11-15: Development of a web-based survey tool to assess change in breast cancer (BrCa) survivor knowledge after receipt of cancer treatment summary and survivorship care plan (SCP). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-11-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Intro: The Institute of Medicine advocates survivorship care plans (SCPs) as tools to improve coordination of care by improving survivor knowledge of follow-up recommendations and future risks. No evidence exists to demonstrate that SCPs impact survivor knowledge of diagnosis, treatment, or future/chronic side effects. Furthermore, there is a lack of information on existing surveys and their ability to assess survivor knowledge regarding these issues, without change over time. The purpose of this research is to report on the development of a survey assessing knowledge of diagnosis, treatment, and side effects in BrCa survivors.
Methods: Using existing literature, two oncologists created 24 questions addressing knowledge of diagnosis, treatment, and side effects. Content experts including breast oncology providers (representing multiple subspecialties), Survey Research Shared Service (SRSS) and patient advocates reviewed and revised the questions. Next, potential questions were administered in a group setting to BrCa survivors to evaluate clarity of instructions and survey wording. The Breast Cancer Knowledge (BreaCK) survey was further revised based on survivor feedback.
For pilot testing, BrCa survivors were recruited from clinic to test BreaCK survey content and clarity. Survey 1 was administered in clinic online. SRSS conducted verbal assessments regarding content after Survey 1. Four weeks later, survivors received Survey 2 via email and answered online. Correct answers were abstracted from the medical record.
Results: Nine subjects completed both surveys. Qualitatively, little intra-subject variation was seen between surveys. Subjects did not feel that the survey was burdensome or intrusive. No subject was able to correctly answer all questions. Final survey adjustments were made based on subject feedback and common incorrect answers encountered when grading the surveys. Specifically, subjects had difficulty understanding “endocrine or hormone therapy.” Furthermore, subjects reported guessing in response to some questions – additional answer categories were added, including “I don't know.”
Conclusion: Survivor knowledge did not change significantly between surveys. This suggests survivor knowledge was not impacted by the survey over the four-week interval. The revised BreaCK survey may be a useful tool for assessing survivor knowledge of diagnosis, treatment and side effects. A larger cohort of BrCa survivors is being recruited, starting Summer 2012, and will be evaluated using the survey.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-11-15.
Collapse
Affiliation(s)
- JL Custer
- University of Wisconsin, Madison, WI
| | - GB Rocque
- University of Wisconsin, Madison, WI
| | | | - NR Jones
- University of Wisconsin, Madison, WI
| | - S Donohue
- University of Wisconsin, Madison, WI
| | - TM Koehn
- University of Wisconsin, Madison, WI
| | | | | | - KB Chen
- University of Wisconsin, Madison, WI
| | - KA Peck
- University of Wisconsin, Madison, WI
| | - MT Tun
- University of Wisconsin, Madison, WI
| | | | - ME Sesto
- University of Wisconsin, Madison, WI
| | | |
Collapse
|
14
|
Ehsani S, Strigel R, Pettke E, Wilke L, Szalkucki L, Tevaarwerk AJ, Wisinski KB. Abstract P3-02-11: Screening Magnetic Resonance Imaging (MRI) of the breast in women at increased lifetime risk for breast cancer: A retrospective single institution study. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-02-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Multiple factors are associated with an increased lifetime risk of breast cancer, including inheritance of an abnormal BRCA 1/2 gene, history of lobular carcinoma in situ (LCIS) or atypical hyperplasia, family history of breast cancer or previous chest wall radiation. In 2007, the American Cancer Society released updated guidelines for breast cancer screening based on risk stratification. These guidelines added annual MRI screening to mammography for women with greater than or equal to a 20–25% lifetime risk. Breast MRI screening trials have consistently demonstrated a higher sensitivity of MRI for malignancy compared with mammography, with an additional cancer yield from MRI of approximately 3%. The purpose of this study was to evaluate MRI screening outcomes in women with an increased risk for breast cancer evaluated in an established breast subspecialty clinic within the University of Wisconsin (UW) Hospital and Clinics.
Methods: Patients (Pts) were included if they were seen by a UW breast center nurse practitioner, medical or surgical oncologist between 1/1/2007–3/1/2011 with a diagnosis code of: family history of breast or ovarian cancer, genetic susceptibility to malignant neoplasm or genetic carrier, Hodgkin's disease, LCIS, or atypical hyperplasia. Pts with a co-existing diagnosis of invasive breast cancer or ductal carcinoma in situ prior to initial encounter were excluded. Demographic information, breast cancer risk factors, estimated lifetime risk of breast cancer and screening recommendations were abstracted from the medical record. Results of subsequent breast imaging examinations (including breast MRI, diagnostic and screening mammography, and image-guided biopsies) were analyzed with the use of the mammography information system (PenRad™).
Results: Of 276 women who met the inclusion criteria, 148 underwent at least 1 screening breast MRI. The majority of MRI screened pts were premenopausal (82%) and Caucasian (96.6%) with a mean age of 42.5 (range 20–68) at their initial encounter. Eighty five percent had a first degree relative with breast cancer and 72.3% of pts undergoing MRI screening had a documented lifetime risk of breast cancer of 20% or greater using a validated model. Within this MRI-screened cohort, 18.2% had a known genetic predisposition to breast cancer. Over the time assessed, 307 MRIs were performed in the 148 pts. Biopsy was recommended and performed based on the results of the MRI in 31 of 307 exams (10%). Ten cancers were detected for a positive predictive value based on biopsy performed of 32% and an overall cancer yield of 3.3% (10 of 307 MRI exams). All cancers were stage 0 - II. All pts are currently with no evidence of disease.
Conclusion: Breast MRI has a high positive predictive value and cancer yield with an acceptable biopsy rate in a diverse group of high risk women undergoing breast MRI at an academic center outside of a clinical trial.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-02-11.
Collapse
Affiliation(s)
- S Ehsani
- University of Wisconsin Carbone Cancer Center, Madison, WI
| | - R Strigel
- University of Wisconsin Carbone Cancer Center, Madison, WI
| | - E Pettke
- University of Wisconsin Carbone Cancer Center, Madison, WI
| | - L Wilke
- University of Wisconsin Carbone Cancer Center, Madison, WI
| | - L Szalkucki
- University of Wisconsin Carbone Cancer Center, Madison, WI
| | - AJ Tevaarwerk
- University of Wisconsin Carbone Cancer Center, Madison, WI
| | - KB Wisinski
- University of Wisconsin Carbone Cancer Center, Madison, WI
| |
Collapse
|
15
|
Njiaju UO, Kolesar JM, Johnston SA, Eickhoff JC, Osterby KR, Poggi LE, Tevaarwerk AJ, Millholland RJ, Oliver KA, Heideman JL, Wisinski KB. Abstract P6-12-02: Use of cytochrome P450 interacting medications in the setting of adjuvant therapy for breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-12-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In the current era of personalized medicine, oral targeted therapies are increasingly used in cancer treatment. In breast cancer, oral anti-estrogen agents have historically been part of standard treatment for hormone receptor positive disease. More recently, other targeted agents have been introduced in the metastatic setting, and are being evaluated as adjuvant therapies. Many oral medications, including anticancer therapies, are metabolized by cytochrome P450 (CYP450) enzymes raising possibility of drug-drug interactions that may affect toxicities or breast cancer outcomes. We sought to evaluate concomitant CYP450 medication use among women seeing a medical oncologist to discuss adjuvant systemic therapy for breast cancer.
Methods: We performed an electronic medical record database extraction. Adult women diagnosed with breast cancer from 1/2008-7/2011 were identified from the University of Wisconsin Hospital and Clinics Cancer Registry. Medication lists were extracted from the first encounter with a medical oncologist after the initial breast cancer diagnosis. Non-systemic medications were excluded. Cytochrome P450 (CYP450) enzyme-interacting medications were categorized as inhibitors, inducers, and/or substrates of specific enzymes including CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, and CYP3A4. CYP450 inhibitors and inducers were further characterized as strong, moderate or weak acting.
Results: A total of 455 women with non-metastatic breast cancer were identified. Mean age was 56.6 years (range of 23–90) and 413 (91%) were Caucasian. Polypharmacy, defined as use of 3–5 medications, was seen in 123 (27.0%) women. A total of 236 (51.9%) women were on 0–4; 109 (24.0%) on 5–10; and 13 (2.9%) on > 10 medications at the time of first encounter with a medical oncologist after a breast cancer diagnosis. 23 (5.05%) women were on strong CYP450 enzyme inhibitors while 72 (15.8%) were on strong inducers. CYP450 enzymes most commonly affected were CYP3A4, CYP2C9, and CYP2D6. Among medications taken on a fixed schedule, levothyroxine and simvastatin were the most commonly used, while simvastatin and ranitidine were the most common CYP450 interacting medications. Further classification of potential CYP450 interactions is ongoing.
Conclusions: A significant proportion of patients were on one or more CYP450 interacting medications in the setting of adjuvant therapy for breast cancer. Given the number of new oral cancer agents that are also CYP450 interacting, the potential for drug interactions should be recognized and appropriate management strategies implemented.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-12-02.
Collapse
Affiliation(s)
- UO Njiaju
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| | - JM Kolesar
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| | - SA Johnston
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| | - JC Eickhoff
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| | - KR Osterby
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| | - LE Poggi
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| | - AJ Tevaarwerk
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| | - RJ Millholland
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| | - KA Oliver
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| | - JL Heideman
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| | - KB Wisinski
- University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics
| |
Collapse
|
16
|
Rocque GB, Onitilo AA, Engel JM, Pettke EN, Boshoven AM, Zhang S, Kim KM, Rishi S, Waack B, Wisinski KB, Tevaarwerk AJ, Burkard ME. P5-18-12: Perception, Practice and Toxicity of Adjuvant Treatment of HER2+ Breast Cancer in Wisconsin. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-18-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
INTRODUCTION: Multiple trastuzumab-containing (neo)adjuvant regimens are used for HER2+ BrCa, but the experience with these regimens in routine practice is not reported. Some oncologists select TCH based on BCIRG 006, whereas others prefer anthracycline-based therapy. We evaluated whether oncologists’ perceptions of these regimens match clinical experience.
METHODS: We surveyed 151 Wisconsin (WI) oncologists regarding factors impacting selection of TCH versus AC-TH; 65 (42%) responded. At the same time, we reviewed 200 cases of HER2+ BrCa treated with adjuvant trastuzumab from 2003 to 2010 at the University of Wisconsin Carbone Cancer Center (UW) and the Marshfield Clinic. We collected baseline patient and tumor characteristics, regimen administered, and toxicities as assessed by lab values, cardiac ejection fraction (EF), hospitalizations, dose reductions/delays, and ability to complete therapy.
RESULTS: Two-thirds of surveyed oncologists prefer anthracycline-based therapy over TCH. Of oncologists preferring TCH, 20 of 23 had been in practice for >10 years. Oncologists perceived that AC-TH and TCH were equally likely to be completed. The majority of physicians select therapy based on patient age and stage, with a preference for AC-TH for node-positive disease and TCH for early stage (T1a-bN0) tumors. Despite BCIRG 006 remaining unpublished at the time of the survey, peer-review publication was cited as the most important factor in selecting this regimen. Although use of granulocyte colony stimulating factor (GCSF) in BCIRG 006 has not reported, 50% of oncologists indicated routine use with cycle 1 of TCH. Of the 200 cases reviewed, 114 women received AC-TH, 48 women received TCH, and 38 had other regimens. The median age was 53 years old, 52% had node positive disease. Acute toxicity trended higher with TCH. For example, there were fewer dose modifications/delays for AC-TH than TCH (31% vs. 46%, p=0.07). This may have been due to common use of GCSF with AC-TH (77% vs. 33% use with TCH). Neutropenic fever (NF) was higher with TCH, reaching 25% incidence when administered without GCSF. However, NF did not occur in the 8 TCH patients who received cycle 1 GCSF. There was no correlation between NF and patient age. The incidence of left ventricular EF decline leading to cessation of trastuzumab was similar for both regimens (19.4% AC-TH vs. 14.6% TCH; p = 0.64). Trastuzumab was completed as planned in 70% of patients. Although EF decline was most common explanation, 13% of early trastuzumab discontinuations occurred for other reasons.
CONCLUSION: TCH and AC-TH are the most commonly administered adjuvant regimens for WI women with HER2+ BrCa. Amongst WI oncologists, TCH is perceived as safer, but is less likely to be recommended for node-positive BrCa. This retrospective analysis suggests that acute myelosuppression is greater for TCH, with a significant rate of NF. Per ASCO guidelines, these data suggest GCSF should be used routinely with TCH due to high rate of FN. We were intrigued that oncologists who have been in practice longer are more likely to choose TCH. The reasons for this are unclear, but are perhaps related to prior experience with long-term cardiotoxicity with AC-TH.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-18-12.
Collapse
Affiliation(s)
- GB Rocque
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - AA Onitilo
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - JM Engel
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - EN Pettke
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - AM Boshoven
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - S Zhang
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - KM Kim
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - S Rishi
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - B Waack
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - KB Wisinski
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - AJ Tevaarwerk
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - ME Burkard
- 1University of Wisconsin Carbone Cancer Center, Madison, WI; The Marshfield Clinic, Weston, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI
| |
Collapse
|
17
|
Ehsani S, Tevaarwerk A, Wilke L, Neuman H, Beckman C, Becker J, Stettner A, Strigel R, Szalkucki L, Burkard M, Wisinski KB. P4-11-21: A Retrospective Analysis of Women at Increased Lifetime Risk for Breast Cancer: Referral Patterns to Subspecialty Providers, Recommendations and Outcomes. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-11-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inheritance of an abnormal BRCA 1/2 gene, a family history of breast cancer (BrCa), or a personal history of lobular carcinoma in situ (LCIS), atypical hyperplasia, or chest wall radiation can significantly increase an individual's lifetime risk for developing BrCa. In 2007, the American Cancer Society (ACS) released updated guidelines for screening in women with a lifetime risk of BrCa ≥20-25%. These guidelines added MRI screening to annual mammography. The objective of our analysis is to characterize patients referred after the release of the 2007 ACS guidelines to subspecialty providers specifically for evaluation of BrCa risk and analyze subsequent screening and risk reduction recommendations in the cohort of patients (pts) with a predicted increased lifetime risk for BrCa.
Methods: Pts seen at a single center (University of Wisconsin [UW]) between 1/2007-3/2011 by medical, surgical and/or gynecology-oncology for an increased lifetime risk of BrCa were identified by billing codes or evaluation in the UW Breast Cancer Prevention, Assessment and Tailored Health Screening (PATHS) Clinic. Pts with a personal history of BrCa prior to 1/2007 are excluded. Patients with a known genetic predisposition to BrCa, family history of breast cancer, or a personal history of LCIS, atypical hyperplasia or chest wall radiation are included in this analysis. All charts will be evaluated for documentation of the individual's lifetime risk of BrCa and method used for risk-assessment, recommended and performed screening tests, concordance with ACS screening guidelines, patient adherence to initial and subsequent screening recommendations, and uptake of risk reduction strategies. Call-back rates for additional or follow-up imaging and/or biopsy following BrCa screening and characteristics of all new BrCa diagnoses will be collected.
Results: 240 eligible pts were seen during the study period. 15% of pts referred had a known genetic predisposition to BrCa. Most pts (75%) were referred for a family history of BrCa. The majority of these pts had a predicted lifetime risk of BrCa in excess of 20%, with less than 10% of patients being referred having a lifetime risk <20%. The remaining pts were referred for a personal history of LCIS, atypical hyperplasia or previous radiation to the chest wall. Results including subspecialty provider BrCa risk assessment, screening and risk-reduction recommendations, patient uptake and adherence, outcomes of screening and characteristics of diagnosed BrCa cases will be presented.
Conclusion: Pts with a predicted increased lifetime risk for BrCa are often evaluated by oncology subspecialty providers. The primary factor related to referral is family history of BrCa. The majority of patients referred to a subspecialty provider have a calculated lifetime risk for BrCa in excess of 20%. This study evaluates provider assessment of BrCa risk and subsequent recommendations for screening and discussion of risk reduction strategies.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-11-21.
Collapse
Affiliation(s)
- S Ehsani
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| | - A Tevaarwerk
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| | - L Wilke
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| | - H Neuman
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| | - C Beckman
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| | - J Becker
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| | - A Stettner
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| | - R Strigel
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| | - L Szalkucki
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| | - M Burkard
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| | - KB Wisinski
- 1University of Wisconsin Carbone Cancer Center, Madison, WI
| |
Collapse
|
18
|
Wisinski K, Mulcahy M, Kuzel TM, Benson AB, Agulnik M, MacVicar GR, Desai D, Yun S, Petrone M, Gradishar W. A phase I study of the oral platinum agent satraplatin (S) in with capecitabine (C) in patients (pts) with advanced solid malignancies. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.13554] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|